Developing a genetic signature to predict drug response in ovarian cancer

There is a lack of personalized treatment options for women with recurrent platinum-resistant ovarian cancer. Outside of bevacizumab and a group of poly ADP-ribose polymerase inhibitors, few options are available to women that relapse. We propose that efficacious drug combinations can be determined...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Hyter, Stephen, Hirst, Jeff, Pathak, Harsh, Pessetto, Ziyan Y., Koestler, Devin C., Raghavan, Rama, Pei, Dong, Godwin, Andrew K.
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5871081/
https://ncbi.nlm.nih.gov/pubmed/29599910
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.23663
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados